Anti-ASPA antibody (ab54849)

Overview

• Product nameAnti-ASPA antibodySee all ASPA primary antibodies ...
• Description
  Mouse monoclonal to ASPA
• Tested applicationsWB more details
• Species reactivity
  Reacts with: Recombinant Fragment
  Predicted to work with: Human
• Immunogen

  Recombinant fragment: MTSCHIAEEH IQKVAIFGGT HGNELTGVFL VKHWLENGAE IQRTGLEVKP FITNPRAVKK CTRYIDCDLN RIFDLENLGK KMSEDLPYEV RRAQEINHLF , corresponding to amino acids 1-101 of Human ASPA

  Run BLAST with Run BLAST with

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: None
  PBS, pH 7.2
• Concentration information loading...
• PurityProtein G purified
• Clonality Monoclonal
• IsotypeIgG2b
• Light chain typekappa
• Research Areas
  • Metabolism
  • Types of disease
  • Cancer

  • Metabolism
  • Pathways and Processes
  • Metabolic signaling pathways
  • Amino acid metabolism

  • Metabolism
  • Pathways and Processes
  • Metabolic signaling pathways
  • Energy transfer pathways
  • Energy Metabolism

  • Signal Transduction
  • Metabolism
  • Amino Acids

  • Signal Transduction
  • Metabolism
  • Energy Metabolism

  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Other

Applications

Target

• FunctionCatalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it act as a scavenger of NAA from body fluids.
• Tissue specificityBrain white matter, skeletal muscle, kidney, adrenal glands, lung and liver.
• Involvement in diseaseDefects in ASPA are the cause of Canavan disease (CAND) [MIM:271900]; also known as spongy degeneration of the brain. CAND is a rare neurodegenerative condition of infancy or childhood characterized by white matter vacuolization and demeylination that gives rise to a spongy appearance. The clinical features are onset in early infancy, atonia of neck muscles, hypotonia, hyperextension of legs and flexion of arms, blindness, severe mental defect, megalocephaly, and death by 18 months on the average.
• Sequence similaritiesBelongs to the AspA/AstE family. Aspartoacylase subfamily.
• Cellular localizationCytoplasm. Nucleus.

Target information above from: UniProt accession P45381 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 443 Human
  • Omim: 608034 Human
  • SwissProt: P45381 Human
  • Unigene: 171142 Human

• Alternative names
  ACY 2 antibodyACY-2 antibodyACY2 antibody

  ACY2_HUMAN antibodyAminoacylase 2 antibodyAminoacylase-2 antibodyAminoacylase2 antibodyASP antibodyASPA antibodyAspartoacylase (aminoacylase 2, Canavan disease) antibodyAspartoacylase (Canavan disease) antibodyAspartoacylase antibodyNUR 7 antibodyNUR7 antibodyOTTMUSP00000006437 antibodyRP23-213I10.1 antibodySmall lethargic antibody

  see all

Anti-ASPA antibody images

• 

  Western blot - ASPA antibody (ab54849)
  Western blot against tagged recombinant protein immunogen using ab54849 ASPA antibody at 1ug/ml. Predicted band size of immunogen is 37 kDa.

  This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.